Zacks Investment Research Upgrades Innocoll AG (INNL) to “Buy”
Innocoll AG (NASDAQ:INNL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The brokerage currently has a $3.75 price target on the specialty pharmaceutical company’s stock. Zacks Investment Research’s price objective suggests a potential upside of 12.28% from the company’s previous close.
According to Zacks, “Innocoll Holdings develops and manufactures pharmaceutical products and medical devices through its proprietary collagen-based technologies. The company’s product include CollaGUARD(Ex-US), CollatampG(R), Septocoll(R), RegenePro(R), Collieva(R), CollaCare(R), Collexa(R) and Zorpreva(TM). It operates primarily in Asia, Australia, Canada, Europe, Latin America, the Middle East and the United States. Innocoll AG, formerly known as Innocoll GmbH, is headquartered in Athlone, Ireland. “
INNL has been the topic of several other reports. JMP Securities reaffirmed a “buy” rating on shares of Innocoll AG in a report on Sunday, November 6th. FBR & Co cut their price target on shares of Innocoll AG from $18.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, November 4th.
Shares of Innocoll AG (NASDAQ:INNL) opened at 3.34 on Wednesday. The company has a 50-day moving average of $5.40 and a 200-day moving average of $6.41. The stock’s market capitalization is $81.34 million. Innocoll AG has a 52 week low of $2.20 and a 52 week high of $12.94.
Innocoll AG (NASDAQ:INNL) last released its quarterly earnings results on Wednesday, August 17th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.11. Innocoll AG had a negative net margin of 1,139.95% and a negative return on equity of 1,226.28%. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $1.04 million. On average, analysts anticipate that Innocoll AG will post ($2.36) EPS for the current year.
Innocoll AG Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically.
Receive News & Stock Ratings for Innocoll AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll AG and related stocks with our FREE daily email newsletter.